Cargando...
Recombinant human erythropoietin stimulates melanoma tumor growth through activation of initiation factor eIF4E
Recombinant human erythropoietin (EPO) is standard treatment for anemia in cancer patients. Recent clinical trials suggest that EPO may accelerate tumor progression and increase mortality. However, the evidence supporting a growth-promoting effect of EPO has remained controversial. Employing an in v...
Guardado en:
| Publicado en: | Oncotarget |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Impact Journals LLC
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5444745/ https://ncbi.nlm.nih.gov/pubmed/28415825 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16331 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|